ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marquette, C.
Right arrow Articles by Tonnel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marquette, C.
Right arrow Articles by Tonnel, A.
Eur Respir J 1995; 8: 22-27
Copyright © ERS Journals Ltd 1995


Clinical Trial

High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma

CH Marquette, B Stach, E Cardot, JF Bervar, F Saulnier, JJ Lafitte, P Goldstein, B Wallaert, and AB Tonnel

The optimal amount of systemic corticosteroids to be used in acute severe asthma remains an unresolved issue. In this double-blind, randomized study we compared two doses of methylprednisolone (1 vs 6 mg.kg-1 q.d.) in asthmatics presenting with an acute severe asthma attack, unresponsive to an intensive beta 2-agonist regimen administered during a run-in period. Concurrent therapy, including oxygen, inhaled and intravenous salbutamol, and aminophylline was strictly standardized. The response was assessed by serial bedside spirometry. The primary outcome measurement was forced expiratory volume in one second (FEV1) (expressed as percentage of predicted values) at 24 and 44 h. The trial was designed in order to achieve a statistical power of 90%. Twenty three patients were included in the low-dose group and 24 in the high-dose group. Both groups were comparable in terms of demographic profiles, history of asthma, and severity of the current attack. Improvement in pulmonary function was similar in both groups. At 44 h, the mean (+/- SD) FEV1 values were 53 +/- 22 and 45 +/- 14% in the low and in the high-dose group respectively (NS). We conclude that high dose systemic corticosteroids offer no further benefit over low-doses in the treatment of severe acute asthma.


This article has been cited by other articles:


Home page
ChestHome page
S. Kayani and D. C. Shannon
Adverse Behavioral Effects of Treatment for Acute Exacerbation of Asthma in Children* : A Comparison of Two Doses of Oral Steroids
Chest, August 1, 2002; 122(2): 624 - 628.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. A. JANTZ and S. A. SAHN
Corticosteroids in Acute Respiratory Failure
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100.
[Full Text]


Home page
ChestHome page
G. Rodrigo and C. Rodrigo
Corticosteroids in the Emergency Department Therapy of Acute Adult Asthma: An Evidence-Based Evaluation
Chest, August 1, 1999; 116(2): 285 - 295.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
P. Demoly, D. Jaffuel, M. Mathieu, H. Sahla, P. Godard, F.-B. Michel, and J. Bousquet
Glucocorticoid insensitive asthma: a one year clinical follow up pilot study
Thorax, December 1, 1998; 53(12): 1063 - 1065.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the European Respiratory Society.